Close
  Indian J Med Microbiol
 

Figure 16: Comparison of IL-23 blockers at week 52/48—tildrakizumab (reSURFACE 2) at week 52; guselkumab (VOYAGE 1) at week 48; risankizumab (PASI 75/PASI 90 data from phase 2 trials and PASI 100 data from UltIMMa 1 trial) at week 52

Figure 16: Comparison of IL-23 blockers at week 52/48—tildrakizumab (reSURFACE 2) at week 52; guselkumab (VOYAGE 1) at week 48; risankizumab (PASI 75/PASI 90 data from phase 2 trials and PASI 100 data from UltIMMa 1 trial) at week 52